Desmopressin increases IGF-binding protein-1 in humans

Area of Science:

• Endocrinology
• Metabolic Research

Background:

• Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) is crucial for IGF-I bioavailability.
• Elevated IGFBP-1 levels are observed in critically ill patients and acute myocardial infarction, but mechanisms remain unclear.
• High vasopressin levels are also reported in these conditions.

Purpose of the Study:

• To investigate the effect of vasopressin on IGFBP-1 levels in human subjects.
• To explore a potential mechanism for elevated IGFBP-1 in certain clinical conditions.

Main Methods:

• A placebo-controlled, cross-over study was conducted in 14 patients with central diabetes insipidus (CDI).
• Patients underwent a desmopressin (a vasopressin analog) washout period before receiving either i.v. saline (placebo) or desmopressin.
• Blood samples were collected over a 24-hour period to measure IGFBP-1 and other regulatory factors.

Main Results:

• Administration of desmopressin led to a significant increase in serum IGFBP-1 levels (375% ± 73%) compared to placebo (252% ± 46%).
• No significant changes were observed in insulin, glucagon, cortisol, IGF-I, or glucose levels.
• The increase in IGFBP-1 was not preceded by a decrease in plasma osmolarity.

Conclusions:

• Desmopressin (DDAVP) administration demonstrably increases serum IGFBP-1 levels in humans.
• Further research is warranted to understand the clinical implications of this vasopressin-IGFBP-1 interaction, particularly in conditions with high IGFBP-1.